<?xml version="1.0" encoding="UTF-8"?>
<html xmlns="http://www.w3.org/1999/xhtml">
 <head charset="UTF-8"/>
 <style> * { font-family : helvetica;} .font18 { font-size : 18; } .font20 { font-size : 20; } .font24 { font-size : 24; } .font10 { font-size : 10; } .font11 { font-size : 11; } .font12 { font-size : 12; } .font13 { font-size : 13; } .font30 { font-size : 30; } .font14 { font-size : 14; } .font15 { font-size : 15; }</style>
 <body>
  <p>
   <span class="font30">;:- </span>
   <span class="font24">treatment </span>
   <span class="font20">patients </span>
   <span class="font18">hepatitis </span>
   <span class="font15">chronic </span>
   <span class="font15">viral </span>
   <span class="font15">virus </span>
   <span class="font14">CMV </span>
   <span class="font14">Med. </span>
   <span class="font14">influenza </span>
   <span class="font14">ribavirin </span>
   <span class="font14">DNA </span>
   <span class="font14">oral </span>
   <span class="font14">used </span>
   <span class="font14">therapy </span>
   <span class="font14">acyclovir </span>
   <span class="font14">ganciclovir </span>
   <span class="font14">herpes </span>
   <span class="font13">HCV </span>
   <span class="font13">antiviral </span>
   <span class="font13">Engl </span>
   <span class="font13">clinical </span>
   <span class="font13">Clin </span>
   <span class="font13">adverse </span>
   <span class="font13">resistance </span>
   <span class="font13">active </span>
   <span class="font13">disease </span>
   <span class="font12">effects </span>
   <span class="font12">transplant </span>
   <span class="font12">approved </span>
   <span class="font12">Infect </span>
   <span class="font12">cidofovir </span>
   <span class="font12">cytomegalovirus </span>
   <span class="font12">Dis. </span>
   <span class="font12">use </span>
   <span class="font12">concentrations </span>
   <span class="font12">drugs </span>
   <span class="font12">genotype </span>
   <span class="font12">renal </span>
   <span class="font12">valganciclovir </span>
   <span class="font12">{border-style </span>
   <span class="font12">HBV </span>
   <span class="font12">HSV </span>
   <span class="font12">acute </span>
   <span class="font12">higher </span>
   <span class="font12">review </span>
   <span class="font12">weeks </span>
   <span class="font12">Ann </span>
   <span class="font12">Oral </span>
   <span class="font12">associated </span>
   <span class="font12">drug </span>
   <span class="font12">effective </span>
   <span class="font12">interferon </span>
   <span class="font12">px;} </span>
   <span class="font12">simplex </span>
   <span class="font11">#ffffff;} </span>
   <span class="font11">available </span>
   <span class="font11">excreted </span>
   <span class="font11">given </span>
   <span class="font11">infection. </span>
   <span class="font11">peginterferon-α </span>
   <span class="font11">prevention </span>
   <span class="font11">combination </span>
   <span class="font11">genital </span>
   <span class="font11">recipients. </span>
   <span class="font11">standard </span>
   <span class="font11">IFN-α </span>
   <span class="font11">SVR </span>
   <span class="font11">hours. </span>
   <span class="font11">however, </span>
   <span class="font11">inhibits </span>
   <span class="font11">patients. </span>
   <span class="font11">peak </span>
   <span class="font11">recurrent </span>
   <span class="font11">respiratory </span>
   <span class="font11">common </span>
   <span class="font11">high </span>
   <span class="font11">infection </span>
   <span class="font11">intravenous </span>
   <span class="font11">lamivudine </span>
   <span class="font11">plus </span>
   <span class="font11">rate </span>
   <span class="font11">treated </span>
   <span class="font11">AIDS. </span>
   <span class="font11">Antimicrob </span>
   <span class="font11">Chemother. </span>
   <span class="font11">Lancet. </span>
   <span class="font11">absorbed </span>
   <span class="font11">competitive </span>
   <span class="font11">immunocompromised </span>
   <span class="font11">trial </span>
   <span class="font11">HIV </span>
   <span class="font11">activity </span>
   <span class="font11">analogue </span>
   <span class="font11">half-life </span>
   <span class="font11">human </span>
   <span class="font11">including </span>
   <span class="font11">inhibitor </span>
   <span class="font11">nucleoside </span>
   <span class="font11">occur </span>
   <span class="font11">plasma </span>
   <span class="font11">rates </span>
   <span class="font11">solid </span>
   <span class="font11">therapy. </span>
   <span class="font11">zoster </span>
   <span class="font11">Acyclovir </span>
   <span class="font11">However, </span>
   <span class="font11">Pharmacother. </span>
   <span class="font11">Study </span>
   <span class="font11">compared </span>
   <span class="font11">liver </span>
   <span class="font11">mechanism </span>
   <span class="font11">organ </span>
   <span class="font11">oseltamivir </span>
   <span class="font11">protease </span>
   <span class="font11">randomized </span>
   <span class="font11">recommended </span>
   <span class="font11">retinitis </span>
   <span class="font11">serum </span>
   <span class="font11">tenofovir </span>
   <span class="font11">valacyclovir </span>
   <span class="font11">viruses </span>
   <span class="font11">Intern </span>
   <span class="font11">glomerular </span>
   <span class="font11">hours </span>
   <span class="font11">polymerase. </span>
   <span class="font11">risk </span>
   <span class="font11">treatment. </span>
   <span class="font11">Ganciclovir </span>
   <span class="font11">IFN </span>
   <span class="font11">Transplant. </span>
   <span class="font11">addition </span>
   <span class="font11">bioavailability </span>
   <span class="font11">development </span>
   <span class="font11">include </span>
   <span class="font11">infected </span>
   <span class="font11">infections. </span>
   <span class="font11">inhibitors </span>
   <span class="font11">major </span>
   <span class="font11">management </span>
   <span class="font11">multifocal </span>
   <span class="font11">nausea, </span>
   <span class="font11">occurs </span>
   <span class="font11">peginterferon-ribavirin </span>
   <span class="font11">progressive </span>
   <span class="font11">prophylaxis </span>
   <span class="font11">ribavirin. </span>
   <span class="font11">severe </span>
   <span class="font11">similar </span>
   <span class="font11">study </span>
   <span class="font11">treating </span>
   <span class="font11">zanamivir </span>
   <span class="font10">(eg, </span>
   <span class="font10">;(suppl </span>
   <span class="font10">Drugs. </span>
   <span class="font10">HIV-infected </span>
   <span class="font10">HSV-, </span>
   <span class="font10">Treatment </span>
   <span class="font10">acyclovir. </span>
   <span class="font10">adefovir </span>
   <span class="font10">al.Peginterferon </span>
   <span class="font10">al.Treatment </span>
   <span class="font10">cellular </span>
   <span class="font10">collab: </span>
   <span class="font10">currently </span>
   <span class="font10">dose </span>
   <span class="font10">duration </span>
   <span class="font10">entecavir </span>
   <span class="font10">gastrointestinal </span>
   <span class="font10">generally </span>
   <span class="font10">hemorrhagic </span>
   <span class="font10">herpes. </span>
   <span class="font10">patients, </span>
   <span class="font10">penciclovir </span>
   <span class="font10">prodrug </span>
   <span class="font10">px; </span>
   <span class="font10">serine </span>
   <span class="font10">telaprevir </span>
   <span class="font10">telbivudine </span>
   <span class="font10">treat </span>
   <span class="font10">tubular </span>
   <span class="font10">virus. </span>
   <span class="font10">viruses. </span>
   <span class="font10">{font-family </span>
   <span class="font10">ALT </span>
   <span class="font10">Agents </span>
   <span class="font10">Foscarnet </span>
   <span class="font10">Ribavirin </span>
   <span class="font10">Valganciclovir </span>
   <span class="font10">analogues </span>
   <span class="font10">days </span>
   <span class="font10">diarrhea, </span>
   <span class="font10">disoproxil </span>
   <span class="font10">efficacy </span>
   <span class="font10">font-size </span>
   <span class="font10">initial </span>
   <span class="font10">levels </span>
   <span class="font10">mild </span>
   <span class="font10">neuraminidase </span>
   <span class="font10">novel </span>
   <span class="font10">placebo-controlled </span>
   <span class="font10">potent </span>
   <span class="font10">prevent </span>
   <span class="font10">preventing </span>
   <span class="font10">receiving </span>
   <span class="font10">reduced </span>
   <span class="font10">reported </span>
   <span class="font10">resistant </span>
   <span class="font10">significantly </span>
   <span class="font10">symptoms </span>
   <span class="font10">therapeutic </span>
   <span class="font10">therapies </span>
   <span class="font10">trial. </span>
   <span class="font10">type </span>
   <span class="font10">utility </span>
   <span class="font10">virus; </span>
   <span class="font10">AIDS </span>
   <span class="font10">Amantadine </span>
   <span class="font10">CHB </span>
   <span class="font10">Cidofovir </span>
   <span class="font10">Drug </span>
   <span class="font10">Famciclovir </span>
   <span class="font10">Interferons </span>
   <span class="font10">JAMA. </span>
   <span class="font10">Lamivudine </span>
   <span class="font10">Oseltamivir </span>
   <span class="font10">Pharmacokinet. </span>
   <span class="font10">RNA </span>
   <span class="font10">action </span>
   <span class="font10">al.A </span>
   <span class="font10">amantadine </span>
   <span class="font10">boceprevir </span>
   <span class="font10">case </span>
   <span class="font10">daily </span>
   <span class="font10">dipivoxil </span>
   <span class="font10">disease. </span>
   <span class="font10">double; </span>
   <span class="font10">effect </span>
   <span class="font10">especially </span>
   <span class="font10">famciclovir </span>
   <span class="font10">fever </span>
   <span class="font10">foscarnet </span>
   <span class="font10">hepatic </span>
   <span class="font10">herpes, </span>
   <span class="font10">immunodeficiency </span>
   <span class="font10">infections </span>
   <span class="font10">kidney </span>
   <span class="font10">lower </span>
   <span class="font10">marrow </span>
   <span class="font10">months </span>
   <span class="font10">multiple </span>
   <span class="font10">mutations </span>
   <span class="font10">neurologic </span>
   <span class="font10">peginterferon </span>
   <span class="font10">polymerase, </span>
   <span class="font10">potential </span>
   <span class="font10">rapid </span>
   <span class="font10">recently </span>
   <span class="font10">reduce </span>
   <span class="font10">replication </span>
   <span class="font10">resistance. </span>
   <span class="font10">specific </span>
   <span class="font10">symptoms, </span>
   <span class="font10">systemic </span>
   <span class="font10">target </span>
   <span class="font10">transplantation. </span>
   <span class="font10">(%) </span>
   <span class="font10">Arch </span>
   <span class="font10">Boceprevir </span>
   <span class="font10">CHB, </span>
   <span class="font10">CHC </span>
   <span class="font10">FDA </span>
   <span class="font10">Intravenous </span>
   <span class="font10">Liver </span>
   <span class="font10">Penciclovir </span>
   <span class="font10">Resistance </span>
   <span class="font10">Valacyclovir </span>
   <span class="font10">Virol. </span>
   <span class="font10">Zanamivir </span>
   <span class="font10">acyclovir, </span>
   <span class="font10">al.; </span>
   <span class="font10">alfa-a </span>
   <span class="font10">anti-HBV </span>
   <span class="font10">anti-HIV </span>
   <span class="font10">border-color </span>
   <span class="font10">border-width </span>
   <span class="font10">concentration </span>
   <span class="font10">considered </span>
   <span class="font10">controlled </span>
   <span class="font10">converted </span>
   <span class="font10">elimination </span>
   <span class="font10">ester </span>
   <span class="font10">events </span>
   <span class="font10">evidence </span>
   <span class="font10">failure </span>
   <span class="font10">filtration </span>
   <span class="font10">following </span>
   <span class="font10">function </span>
   <span class="font10">gene </span>
   <span class="font10">highly </span>
   <span class="font10">histologic </span>
   <span class="font10">incidence </span>
   <span class="font10">inhibition </span>
   <span class="font10">kinase </span>
   <span class="font10">kinases </span>
   <span class="font10">lamivudine, </span>
   <span class="font10">leukoencephalopathy </span>
   <span class="font10">mutation </span>
   <span class="font10">new </span>
   <span class="font10">nucleos(t)ide </span>
   <span class="font10">pharmacokinetics </span>
   <span class="font10">polymerase </span>
   <span class="font10">possess </span>
   <span class="font10">properties </span>
   <span class="font10">provides </span>
   <span class="font10">rapidly </span>
   <span class="font10">rash </span>
   <span class="font10">resistance, </span>
   <span class="font10">resolution </span>
   <span class="font10">results </span>
   <span class="font10">retinitis. </span>
   <span class="font10">serving </span>
   <span class="font10">solid; </span>
   <span class="font10">substrate </span>
   <span class="font10">syncytial </span>
   <span class="font10">syndrome </span>
   <span class="font10">terminal </span>
   <span class="font10">times </span>
   <span class="font10">topical </span>
   <span class="font10">toxicity </span>
   <span class="font10">varicella </span>
   <span class="font10">{font-style </span>
   <span class="font10">{font-weight </span>
   <span class="font10">(HN) </span>
   <span class="font10">(for </span>
   <span class="font10">CHC. </span>
   <span class="font10">Drugs </span>
   <span class="font10">EBV. </span>
   <span class="font10">Entecavir </span>
   <span class="font10">Fanconi </span>
   <span class="font10">GroupA </span>
   <span class="font10">HBeAg-negative </span>
   <span class="font10">HBeAg-positive </span>
   <span class="font10">HHV-, </span>
   <span class="font10">HSV- </span>
   <span class="font10">Hepatology. </span>
   <span class="font10">Interferon-α </span>
   <span class="font10">Pharmacol. </span>
   <span class="font10">Rev. </span>
   <span class="font10">United </span>
   <span class="font10">VZV, </span>
   <span class="font10">VZV. </span>
   <span class="font10">achieves </span>
   <span class="font10">acyclic </span>
   <span class="font10">administration </span>
   <span class="font10">al.Efficacy </span>
   <span class="font10">al.Telaprevir </span>
   <span class="font10">alfa-b </span>
   <span class="font10">anemia </span>
   <span class="font10">article </span>
   <span class="font10">binding </span>
   <span class="font10">bold </span>
   <span class="font10">bone </span>
   <span class="font10">caused </span>
   <span class="font10">cell </span>
   <span class="font10">clinically </span>
   <span class="font10">cohort </span>
   <span class="font10">coinfected </span>
   <span class="font10">combined </span>
   <span class="font10">commonly </span>
   <span class="font10">courier; </span>
   <span class="font10">demonstrated </span>
   <span class="font10">depression </span>
   <span class="font10">develop </span>
   <span class="font10">discuss </span>
   <span class="font10">disorders </span>
   <span class="font10">does </span>
   <span class="font10">double-blind </span>
   <span class="font10">elderly </span>
   <span class="font10">em; </span>
   <span class="font10">encephalitis </span>
   <span class="font10">extensive </span>
   <span class="font10">fatigue, </span>
   <span class="font10">ganciclovir. </span>
   <span class="font10">gene, </span>
   <span class="font10">hepatitis, </span>
   <span class="font10">hours, </span>
   <span class="font10">immunocompetent </span>
   <span class="font10">increased </span>
   <span class="font10">infection, </span>
   <span class="font10">infections, </span>
   <span class="font10">inhibit </span>
   <span class="font10">intracellular </span>
   <span class="font10">lamivudine. </span>
   <span class="font10">limited </span>
   <span class="font10">literature. </span>
   <span class="font10">long-term </span>
   <span class="font10">main </span>
   <span class="font10">mainly </span>
   <span class="font10">mechanisms </span>
   <span class="font10">metabolism. </span>
   <span class="font10">metabolite </span>
   <span class="font10">metabolite, </span>
   <span class="font10">metabolized </span>
   <span class="font10">monotherapy </span>
   <span class="font10">orally </span>
   <span class="font10">pain, </span>
   <span class="font10">pandemic </span>
   <span class="font10">patient </span>
   <span class="font10">peripheral </span>
   <span class="font10">phosphorylated </span>
   <span class="font10">poorly </span>
   <span class="font10">preexisting </span>
   <span class="font10">previously </span>
   <span class="font10">primary </span>
   <span class="font10">prolonged </span>
   <span class="font10">properties, </span>
   <span class="font10">pt;} </span>
   <span class="font10">pulmonary </span>
   <span class="font10">rash. </span>
   <span class="font10">received </span>
   <span class="font10">reduces </span>
   <span class="font10">regimen </span>
   <span class="font10">relapse </span>
   <span class="font10">require </span>
   <span class="font10">response </span>
   <span class="font10">resulted </span>
   <span class="font10">retinal </span>
   <span class="font10">rimantadine </span>
   <span class="font10">rimantadine. </span>
   <span class="font10">safety </span>
   <span class="font10">secretion. </span>
   <span class="font10">started </span>
   <span class="font10">suppression </span>
   <span class="font10">syndrome. </span>
   <span class="font10">synthesis </span>
   <span class="font10">thymidine </span>
   <span class="font10">triphosphate. </span>
   <span class="font10">undergoes </span>
   <span class="font10">untreated </span>
   <span class="font10">versus </span>
   <span class="font10">virus, </span>
  </p>
 </body>
</html>
